Led by ex-Springworks exec, Pyxis forges deal to gain access to Pfizer’s ADCs, platform tech 

Pyxis CEO Lara Sullivan has struck a deal with her former employer, Pfizer, that adds two preclinical therapies to the biotech’s pipeline as well as a license to the pharma’s ADC platform to develop more programs.

As Pfizer Inc. (NYSE:PFE) out-licenses rights to preclinical antibody-drug conjugates that will now be called PYX-201 and PYX-203, the pharma will receive an upfront payment and gain an equity stake in the biotech. It will also be eligible for milestones and royalties, and intends to invest in Pyxis Oncology Inc. from its Pfizer Ventures arm...